Intrinsiqq
Park Ha Biological Technology Co., Ltd. logoPark Ha Biological Technology Co., Ltd.BYAH
$2.20-7.95%
Park Ha Biological Technology Co., Ltd. logo

Park Ha Biological Technology Co., Ltd.

BYAH

$2.20

-$0.19 (-7.95%)

⊜ Compare
ProfitabilityUnprofitableGrowthSteady growthCash FlowCash burnValuationN/A
What stands out

The business is unprofitable at the operating level (-956.45% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.

What's changing

Revenue grew 6.0%, steady but not accelerating. Margins contracted 989.8pp, which offsets some of the top-line progress.

What deserves caution

Free cash flow declined 100% versus the prior year, cash generation momentum has weakened. ROIC dropped from 36.54% to -663.41%, capital efficiency is deteriorating.

Price History

-88.6%

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$1M
EPS-$46.50
P/E-0.05
P/FCF-387.76
EV/EBITDA0.10
FCF Yield—
Div. Yield—
Net Debt/FCF1213.4x
52-Week Range
$0.44$6.25

Profitability & Returns

Revenue (TTM)

$3M

▲ +6.0% YoY

Net Income (TTM)

-$24M

▼ -5191.3% YoY

Op. Margin

-956.45%

▼ -989.8pp YoY

ROIC

-663.41%

▼ -699.9pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$3K

▼ -100.3% YoY

Op. Cash Flow (TTM)

$86K

▼ -91.1% YoY

Net Debt

-$4M

Net Cash Position

Cash & Equiv.

$4M

3Y CAGR: +9.6%

Continue Research

Is Park Ha Biological Technology Co. (BYAH) overvalued?

Park Ha Biological Technology Co. (BYAH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.

On quality, Park Ha Biological Technology Co. scores 31/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.

Frequently asked

Is Park Ha Biological Technology Co. a high-quality business?+

Park Ha Biological Technology Co. scores 31 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -956.5% operating margin and a -663.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Is Park Ha Biological Technology Co. a good stock to buy right now?+

That depends on valuation and quality together, not either alone. you should weigh BYAH's valuation and scores 31/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.

Related stocks: Household & Personal Products

Spot a number that looks wrong?

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.